Russian Pharmaceutical Industry Leader
Pharmasyntez history

Pharmasyntez history

Vikram Puniya

We have passed a long way over the last 20 years. Back in 1997 it was very hard to predict that Russia could be a competitive country in the field of innovative pharmaceutical products. It was even more difficult to suppose that Russian medicine could survive without having vital and major drugs imported. But we did it: constructed five factories, mastered the most advanced technologies, took leading positions in the Russian pharmaceutical market, provided thousands of people with permanent job and paid billion rubles of taxes. The company continuously updates production equipment, develops new drug production technologies, enhances work methods in the sphere of management and sales.

Our priorities are invariable: they are concentrated on development and production of high-quality socially important medicines and ensuring their availability to patients and healthcare institutions.

Pharmasyntez history
  • 1997
  • 1999
  • 2000
  • 2002
  • 2003
  • 2004
  • 2005
  • 2006
  • 2009
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2017
  • 1997

    • Pharmasyntez company was founded in Irkutsk in 1997. The first factory was opened in 1999. It was the very place where the first Pharmasyntez antitubercular medicine was created. This was the beginning of active production of foreign generics and development of new unique medicines. Within the next several years the nomenclature of the drugs for the treatment of tuberculosis produced by Pharmasyntez expanded to more than 50 products.

  • 1999

    • Start of antitubercular medicines production
    • Production of Rifampicin, the first medicine in the Pharmasyntez's portfolio

  • 2000

    • Start of medicines regular supplies to the largest pharmaceutical distributors of Russia

  • 2002

    • Start of the research of a new antitubercular medicine Perchlozone®. After a series of clinical tests and thanks to its capability to increase complex therapy efficiency for tuberculosis with multiple drug resistance, Perchlozone was included subsequently in the VED list. Now it is registered and is actively used in 120 countries in the world.
    • Pharmasyntez is the first company to resume production of medicine PAS in Russia. It was produced in a new dosage form of enteric-coated granules

  • 2003

    • The branch of JSC Pharmasyntez opened in Moscow

  • 2004

    • The second plant of Pharmasyntez was opened in Ussuriysk. It is focused on production of infusion solutions

  • 2005

    • Start of the infusions solutions production in Ussuriysk

  • 2006

    • A new production site was started

  • 2009

    • Production line in Irkutsk was upgraded
    • The new product lines for the main, pilot, and small-scale production were launched.

  • 2011

    • The design works of the Pharmasyntez-Nord plant in St. Petersburg was started. The plan was to start producing modern cytostatic drugs in solid dosage forms, lyophilized powders, and concentrated solutions. Also it was planned to release biological products, including monoclonal antibodies, which could be effective for the treatment of allergic, catarrhal, and other diseases.

  • 2012

    • The production line for the solid dosage forms was started.
    • The Pharmasyntes has the widest product line of 50 items of tuberculosis treatment drugs in Russia

  • 2013

    • Start of antiretroviral drugs production in 2013 at the Irkutsk plant. The number of produced antibiotics is significantly increased in 2014.

  • 2014

    • In 2014 the investment council at the Government of the Irkutsk region approved the project of the Pharmasyntez company to construct the plant to produce hi-tech pharmaceutical substances in Bratsk.

  • 2015

    • In 2015 the production of infusion solutions and hormonal drugs started at Tyumen plant - Pharmasyntez-Tyumen.
    • Since 2015 the company has registered and produced four antitumoral drugs, and it is planned to expand product portfolio in 2017 by 10 items, including drugs for the treatment of hepatitis and also a diabetes mellitus type 2.

  • 2017

    • The Pharmasyntez group is in TOP-3 of the the fastest-growing Russian pharmaceutical companies, producing over 50% of all antituberculous drugs and 45% of all antiretroviral drugs in the Russian market.
    • The product portfolio includes 115 medicines in various forms and dosages. Production is actively exported to Kazakhstan, Uzbekistan, Kyrgyzstan, Belarus, and other countries.